Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R-ICE vs R-ICE as Second-Line Therapy in Relapsed or Primary Refractory DLBCL
2023-508259-38-00Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) and 4 more (2 arms), sponsored by GWT-TUD. Primary endpoint: Event-free survival (EFS). Started Feb 2024; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on 2023-508259-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508259-38-00.